Headquartered in Somerset, NJ Fiscal year ends December NASDAQ: LEGN legendbiotech.com
Legend Biotech Corporation is the largest standalone cell therapy company, with over 3,200 employees, focused on developing and commercializing CAR-T cell therapies for cancer treatment. Its commercial product, CARVYKTI (ciltacabtagene autoleucel), is a one-time CAR-T treatment for relapsed or refractory multiple myeloma, developed and marketed in collaboration with Johnson & Johnson (via Janssen). CARVYKTI is available across 19 global markets at 348 treatment sites. Beyond its flagship product, Legend Biotech is building a diversified pipeline of next-generation cell therapies including LB2501 (an in vivo CD19/CD20 dual-targeting CAR-T for B-cell non-Hodgkin lymphoma) and LB2102 (a DLL3-targeted CAR-T for small-cell lung cancer and large-cell neuroendocrine carcinoma, licensed to Novartis). The company reports under IFRS and trades on NASDAQ under the ticker LEGN. Updated
With all eyes locked on this morning's CPI release and the Strait of Hormuz nearly shut down, Wall Street analysts are already repositioning across hospitality, pharma, and tech before the market even…
Legend Biotech just posted a quarter that flipped a key narrative for LEGN shareholders, but with a CEO transition underway and the stock still down sharply over the past year, the real…
Big Pharma's patent cliffs are forcing acquirers to hunt for revenue-producing biotech assets before rivals snap them up, and three names keep surfacing in deal speculation. One already has a natural buyer…
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth. Five therapeutic categories are absorbing most strategic capital: radiopharmaceuticals, next-gen GLP-1,…
Pre-Market Stock Futures: The futures are trading higher this morning, following a solid bounce-back rally across the major indices on Wednesday, after the worst day for stocks since October. Stocks were headed…
Legend Biotech Corporation is the largest standalone cell therapy company, with over 3,200 employees, focused on developing and commercializing CAR-T cell therapies for cancer treatment.
The Wall Street consensus 12-month price target for LEGN is $46.19. LEGN price prediction →
